Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Akebia Therapeutics (AKBA) Equity Ratio (2016 - 2025)

Akebia Therapeutics (AKBA) has disclosed Equity Ratio for 8 consecutive years, with 0.22 as the latest value for Q4 2024.

  • On a quarterly basis, Equity Ratio fell 76.15% to 0.22 in Q4 2024 year-over-year; TTM through Dec 2024 was 0.22, a 76.15% decrease, with the full-year FY2024 number at 0.22, down 76.15% from a year prior.
  • Equity Ratio was 0.22 for Q4 2024 at Akebia Therapeutics, up from 0.24 in the prior quarter.
  • In the past five years, Equity Ratio ranged from a high of 0.5 in Q1 2020 to a low of 0.24 in Q3 2024.
  • A 5-year average of 0.1 and a median of 0.04 in 2022 define the central range for Equity Ratio.
  • Peak YoY movement for Equity Ratio: decreased 20.02% in 2020, then tumbled 1002.31% in 2023.
  • Akebia Therapeutics' Equity Ratio stood at 0.38 in 2020, then tumbled by 63.14% to 0.14 in 2021, then tumbled by 89.49% to 0.01 in 2022, then plummeted by 961.44% to 0.13 in 2023, then tumbled by 76.15% to 0.22 in 2024.
  • Per Business Quant, the three most recent readings for AKBA's Equity Ratio are 0.22 (Q4 2024), 0.24 (Q3 2024), and 0.12 (Q1 2024).